The 2022 top 100 bio­phar­ma in­vestors: A look back on boom times

RA Cap­i­tal dom­i­nat­ed the crossover game in 2021, run­ning the ta­ble as a host of biotechs an­gled for a quick leap on­to the pub­lic mar­ket. The RA crew, head­ed by Pe­ter Kolchin­sky and Raj Shah, even beat out Or­biMed last year on the to­tal num­ber of new deals ex­e­cut­ed, with both rep­re­sent­ing big spikes over 2020 deal lev­els.

Or­biMed, though, was in­volved with a larg­er amount of cash go­ing in­to new deals, typ­i­cal for the heavy­weight play­er in this in­dus­try. And if you ex­plore the charts be­low the top 100, you’ll see how the rush to the mar­ket helped tilt the scales to­ward ear­li­er stage biotechs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER